Kathleen P. Gallagher Avidity Biosciences, Inc. (RNA) insider trading activity

Kathleen P. Gallagher is Chief Program Officer of Avidity Biosciences, Inc.. Currently has a direct ownership of 80,838 shares of RNA, which is worth approximately $5.72 Million. The most recent transaction as insider was on Dec 17, 2025, when has been sold 41,366 shares (Common Stock) at a price of $71.87 per share, resulting in proceeds of $2,972,974. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 80.8K

61.02% 3M change

n/a 12M change

Total Value Held $5.72 Million

Kathleen P. Gallagher Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 17 2025	SELL Payment of exercise price or tax liability	$2,972,974 $71.87 p/Share	41,366 Reduced 33.85%	80,838 Common Stock
Dec 17 2025	BUY Grant, award, or other acquisition	-	72,000 Added 37.07%	122,204 Common Stock
Sep 02 2025	SELL Open market or private sale	$8,914 $47.42 p/Share	188 Reduced 0.37%	50,204 Common Stock
Jun 17 2025	SELL Open market or private sale	$27,548 $30.24 p/Share	911 Reduced 1.78%	50,392 Common Stock
Jun 02 2025	SELL Open market or private sale	$190,819 $32.48 p/Share	5,875 Reduced 10.41%	50,554 Common Stock
Jun 02 2025	BUY Exercise of conversion of derivative security	$97,818 $16.65 p/Share	5,875 Added 9.43%	56,429 Common Stock
May 01 2025	SELL Open market or private sale	$190,350 $32.4 p/Share	5,875 Reduced 10.41%	50,554 Common Stock

May 01 2025	BUY Exercise of conversion of derivative security	$97,818 $16.65 p/Share	5,875 Added 9.43%	56,429 Common Stock
Apr 01 2025	SELL Open market or private sale	$163,501 $27.83 p/Share	5,875 Reduced 10.41%	50,554 Common Stock
Apr 01 2025	BUY Exercise of conversion of derivative security	$92,120 $15.68 p/Share	5,875 Added 10.35%	50,883 Common Stock
Mar 03 2025	SELL Open market or private sale	$172,783 $29.41 p/Share	5,875 Reduced 10.41%	50,554 Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	$86,362 $14.7 p/Share	5,875 Added 9.43%	56,429 Common Stock
Feb 03 2025	SELL Open market or private sale	$188,939 $32.16 p/Share	5,875 Reduced 10.41%	50,554 Common Stock
Feb 03 2025	BUY Exercise of conversion of derivative security	$97,818 $16.65 p/Share	5,875 Added 9.43%	56,429 Common Stock
Jan 22 2025	SELL Open market or private sale	$169,770 $30.16 p/Share	5,629 Reduced 10.02%	50,554 Common Stock
Jan 21 2025	SELL Open market or private sale	$108,127 $28.59 p/Share	3,782 Reduced 6.31%	56,183 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	25,000 Added 29.42%	59,965 Common Stock

KPG

Kathleen P. Gallagher

Chief Program Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNA shares.

Notify only if

Value

Insider Trading

Get notified when an Avidity Biosciences, Inc. insider buys or sells RNA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Avidity Biosciences, Inc.

Track Activities on RNA

Account